{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:21Z","timestamp":1787020101012,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Glucocorticoids contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Natural killer T cells play a role in the pathogenesis of NAFLD and response to steroids. The present study aimed to determine the role of CD1d in steroid-mediated metabolic derangement and the steroid-protective effect of glycosphingolipids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Ten groups of mice were studied. Steroids were orally administered to C57BL\/6 mice to assess the therapeutic effect of \u03b2-glucosylceramide (GC) on the development of steroid-mediated liver damage and metabolic derangements. The role of CD1d in the pathogenesis of steroid-induced liver damage and in mediating the hepatoprotective effect of GC was studied in CD1d\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A model of oral administration of steroids was established, resulting in insulin resistance, hyperinsulinemia, hypertriglyceridemia, liver steatosis, and hepatocellular injury. Steroid administration to CD1d\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice was associated with hyperglycemia and hypertriglyceridemia. However, CD1d\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice did not manifest marked steroid-induced steatosis. GC treatment alleviated steroid-associated metabolic derangements and liver injury independent of CD1d expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A steroid-mediated model of NAFLD and metabolic derangements was established in which steroid-mediated steatosis was CD1d-dependent while steroid-induced liver necrosis, inflammation, and metabolic changes were CD1d-independent, which may support a dichotomy between steatosis and steatohepatitis in NAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02242-9","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T12:02:42Z","timestamp":1649332962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Steroid-mediated liver steatosis is CD1d-dependent, while steroid-induced liver necrosis, inflammation, and metabolic changes are CD1d-independent"],"prefix":"10.1186","volume":"22","author":[{"given":"Tomer","family":"Adar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Ben Ya\u2019acov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehudit","family":"Shabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Zolotarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Ilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"2242_CR1","first-page":"G1141","volume":"272","author":"P Letteron","year":"1997","unstructured":"Letteron P, Brahimi-Bourouina N, Robin MA, et al. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol. 1997;272:G1141\u201350.","journal-title":"Am J Physiol"},{"key":"2242_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3727\/105221609788681213","volume":"14","author":"Y Jia","year":"2009","unstructured":"Jia Y, Viswakarma N, Fu T, et al. Conditional ablation of mediator subunit MED1 (MED1\/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. Gene Expr. 2009;14:291\u2013306.","journal-title":"Gene Expr"},{"key":"2242_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1194\/jlr.M800013-JLR200","volume":"49","author":"B Manmontri","year":"2008","unstructured":"Manmontri B, Sariahmetoglu M, Donkor J, et al. Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically. J Lipid Res. 2008;49:1056\u201367.","journal-title":"J Lipid Res"},{"key":"2242_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","volume":"60","author":"AJ Peckett","year":"2011","unstructured":"Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60:1500\u201310.","journal-title":"Metabolism"},{"key":"2242_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1677\/JOE-08-0054","volume":"197","author":"DP Macfarlane","year":"2008","unstructured":"Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197:189\u2013204.","journal-title":"J Endocrinol"},{"key":"2242_CR6","first-page":"R455","volume":"277","author":"L Mantha","year":"1999","unstructured":"Mantha L, Palacios E, Deshaies Y. Modulation of triglyceride metabolism by glucocorticoids in diet-induced obesity. Am J Physiol. 1999;277:R455\u201364.","journal-title":"Am J Physiol"},{"key":"2242_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jsbmb.2015.07.020","volume":"154","author":"CP Woods","year":"2015","unstructured":"Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015;154:94\u2013103.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"2242_CR8","first-page":"S69","volume":"19","author":"DN Brindley","year":"1995","unstructured":"Brindley DN. Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Int J Obes Relat Metab Disord. 1995;19(Suppl 1):S69-75.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2242_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1756283X11430859","volume":"5","author":"JM Kneeman","year":"2012","unstructured":"Kneeman JM, Misdraji J, Corey KE. Secondary causes of non-alcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5:199\u2013207.","journal-title":"Therap Adv Gastroenterol"},{"key":"2242_CR10","doi-asserted-by":"publisher","first-page":"E654","DOI":"10.1152\/ajpendo.00453.2006","volume":"292","author":"D Qi","year":"2007","unstructured":"Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab. 2007;292:E654\u201367.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2242_CR11","doi-asserted-by":"publisher","first-page":"G850","DOI":"10.1152\/ajpgi.00378.2011","volume":"302","author":"AM D'Souza","year":"2012","unstructured":"D\u2019Souza AM, Beaudry JL, Szigiato AA, et al. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. Am J Physiol Gastrointest Liver Physiol. 2012;302:G850\u201363.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2242_CR12","doi-asserted-by":"publisher","first-page":"207534","DOI":"10.1155\/2015\/207534","volume":"2015","author":"RA Rebolledo","year":"2015","unstructured":"Rebolledo RA, Liu B, Akhtar MZ, et al. Steroid anti-inflammatory effects did not improve organ quality in brain-dead rats. Biomed Res Int. 2015;2015:207534.","journal-title":"Biomed Res Int"},{"key":"2242_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/apt.13023","volume":"41","author":"M Robles-Diaz","year":"2015","unstructured":"Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015;41:116\u201325.","journal-title":"Aliment Pharmacol Ther"},{"key":"2242_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1210\/jc.2014-4463","volume":"100","author":"D Covelli","year":"2015","unstructured":"Covelli D, Vannucchi G, Campi I, et al. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100:1731\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"2242_CR15","doi-asserted-by":"publisher","first-page":"850836","DOI":"10.1155\/2012\/850836","volume":"2012","author":"K Tajiri","year":"2012","unstructured":"Tajiri K, Shimizu Y. Role of NKT cells in the pathogenesis of NAFLD. Int J Hepatol. 2012;2012:850836.","journal-title":"Int J Hepatol"},{"key":"2242_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fimmu.2016.00617","volume":"7","author":"G Hodge","year":"2016","unstructured":"Hodge G, Hodge S. Steroid resistant CD8(+)CD28(null) NKT-like pro-inflammatory cytotoxic cells in chronic obstructive pulmonary disease. Front Immunol. 2016;7:617.","journal-title":"Front Immunol"},{"key":"2242_CR17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/hep.26748","volume":"59","author":"HJ Kwon","year":"2014","unstructured":"Kwon HJ, Won YS, Park O, et al. Opposing effects of prednisolone treatment on T\/NKT cell- and hepatotoxin-mediated hepatitis in mice. Hepatology. 2014;59:1094\u2013106.","journal-title":"Hepatology"},{"key":"2242_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.14218\/JCTH.2017.00071","volume":"6","author":"M Mizrahi","year":"2018","unstructured":"Mizrahi M, Adar T, Lalazar G, et al. Glycosphingolipids prevent APAP and HMG-CoA reductase inhibitors-mediated liver damage: a novel method for \u201csafer drug\u201d formulation that prevents drug-induced liver injury. J Clin Transl Hepatol. 2018;6:127\u201334.","journal-title":"J Clin Transl Hepatol"},{"key":"2242_CR19","first-page":"151","volume":"7","author":"E Zigmond","year":"2014","unstructured":"Zigmond E, Tayer-Shifman O, Lalazar G, et al. beta-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model. J Inflamm Res. 2014;7:151\u20138.","journal-title":"J Inflamm Res"},{"key":"2242_CR20","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1152\/ajpendo.90634.2008","volume":"296","author":"E Zigmond","year":"2009","unstructured":"Zigmond E, Zangen SW, Pappo O, et al. Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab. 2009;296:E72\u20138.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2242_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jaut.2008.07.003","volume":"31","author":"E Zigmond","year":"2008","unstructured":"Zigmond E, Shalev Z, Pappo O, et al. NKT lymphocyte polarization determined by microenvironment signaling: a role for CD8+ lymphocytes and beta-glycosphingolipids. J Autoimmun. 2008;31:188\u201395.","journal-title":"J Autoimmun"},{"key":"2242_CR22","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1194\/jlr.M800113-JLR200","volume":"49","author":"G Lalazar","year":"2008","unstructured":"Lalazar G, Ben Ya\u2019acov A, Eliakim-Raz N, et al. Beta-glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping. J Lipid Res. 2008;49:1884\u201393.","journal-title":"J Lipid Res"},{"key":"2242_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1089\/jmf.2016.3753","volume":"20","author":"G Lalazar","year":"2017","unstructured":"Lalazar G, Zigmond E, Weksler-Zangen S, et al. Oral Administration of beta-glucosylceramide for the treatment of insulin resistance and nonalcoholic steatohepatitis: results of a double-blind, placebo-controlled trial. J Med Food. 2017;20:458\u201364.","journal-title":"J Med Food"},{"key":"2242_CR24","doi-asserted-by":"publisher","first-page":"G917","DOI":"10.1152\/ajpgi.00105.2005","volume":"289","author":"M Margalit","year":"2005","unstructured":"Margalit M, Abu Gazala S, Alper R, et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol. 2005;289:G917\u201325.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2242_CR25","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/apt.13833","volume":"44","author":"Y Ilan","year":"2016","unstructured":"Ilan Y. Review article: novel methods for the treatment of non-alcoholic steatohepatitis\u2014targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. Aliment Pharmacol Ther. 2016;44:1168\u201382.","journal-title":"Aliment Pharmacol Ther"},{"key":"2242_CR26","doi-asserted-by":"publisher","first-page":"G1102","DOI":"10.1152\/ajpgi.00095.2016","volume":"310","author":"Y Ilan","year":"2016","unstructured":"Ilan Y. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2016;310:G1102\u201317.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2242_CR27","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fimmu.2019.01143","volume":"10","author":"Y Ilan","year":"2019","unstructured":"Ilan Y. Beta-glycosphingolipids as mediators of both inflammation and immune tolerance: a manifestation of randomness in biological systems. Front Immunol. 2019;10:1143.","journal-title":"Front Immunol"},{"key":"2242_CR28","doi-asserted-by":"publisher","first-page":"104157","DOI":"10.1016\/j.cellimm.2020.104157","volume":"355","author":"T Adar","year":"2020","unstructured":"Adar T, Shankar Lankalapalli R, Bittman R, et al. The assembly of glycosphingolipid determines their immunomodulatory effect: a novel method for structure-based design of immunotherapy. Cell Immunol. 2020;355:104157.","journal-title":"Cell Immunol"},{"key":"2242_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","volume":"226","author":"J Folch","year":"1957","unstructured":"Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497\u2013509.","journal-title":"J Biol Chem"},{"key":"2242_CR30","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.3748\/wjg.v16.i38.4762","volume":"16","author":"A Federico","year":"2010","unstructured":"Federico A, D\u2019Aiuto E, Borriello F, et al. Fat: a matter of disturbance for the immune system. World J Gastroenterol. 2010;16:4762\u201372.","journal-title":"World J Gastroenterol"},{"key":"2242_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1126\/science.7624776","volume":"269","author":"MA Pelleymounter","year":"1995","unstructured":"Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob\/ob mice. Science. 1995;269:540\u20133.","journal-title":"Science"},{"key":"2242_CR32","doi-asserted-by":"publisher","first-page":"9765","DOI":"10.1073\/pnas.0908771107","volume":"107","author":"Y Ilan","year":"2010","unstructured":"Ilan Y, Maron R, Tukpah AM, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob\/ob mice. Proc Natl Acad Sci USA. 2010;107:9765\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2242_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/jpet.106.104950","volume":"319","author":"M Margalit","year":"2006","unstructured":"Margalit M, Shalev Z, Pappo O, et al. Glucocerebroside ameliorates the metabolic syndrome in OB\/OB mice. J Pharmacol Exp Ther. 2006;319:105\u201310.","journal-title":"J Pharmacol Exp Ther"},{"key":"2242_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/path.1950","volume":"209","author":"E Elinav","year":"2006","unstructured":"Elinav E, Pappo O, Sklair-Levy M, et al. Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob\/ob mice and is associated with intrahepatic CD8 trapping. J Pathol. 2006;209:121\u20138.","journal-title":"J Pathol"},{"key":"2242_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/hep.510310313","volume":"31","author":"M Guebre-Xabier","year":"2000","unstructured":"Guebre-Xabier M, Yang S, Lin HZ, et al. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology. 2000;31:633\u201340.","journal-title":"Hepatology"},{"key":"2242_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1309","volume":"4","author":"DI Godfrey","year":"2004","unstructured":"Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what\u2019s in a name? Nat Rev Immunol. 2004;4:231\u20137.","journal-title":"Nat Rev Immunol"},{"key":"2242_CR37","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/hep.20826","volume":"42","author":"Z Li","year":"2005","unstructured":"Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with non-alcoholic fatty liver disease. Hepatology. 2005;42:880\u20135.","journal-title":"Hepatology"},{"key":"2242_CR38","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/S0026-0495(98)90304-3","volume":"47","author":"BL Black","year":"1998","unstructured":"Black BL, Croom J, Eisen EJ, et al. Differential effects of fat and sucrose on body composition in A\/J and C57BL\/6 mice. Metabolism. 1998;47:1354\u20139.","journal-title":"Metabolism"},{"key":"2242_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1073\/pnas.0408288102","volume":"102","author":"J Schmieg","year":"2005","unstructured":"Schmieg J, Yang G, Franck RW, et al. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci USA. 2005;102:1127\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2242_CR40","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1194\/jlr.M003004","volume":"51","author":"J Hua","year":"2010","unstructured":"Hua J, Ma X, Webb T, et al. Dietary fatty acids modulate antigen presentation to hepatic NKT cells in non-alcoholic fatty liver disease. J Lipid Res. 2010;51:1696\u2013703.","journal-title":"J Lipid Res"},{"key":"2242_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/imm.13002","volume":"155","author":"L Russo","year":"2018","unstructured":"Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in obesity. Immunology. 2018;155:407\u201317.","journal-title":"Immunology"},{"key":"2242_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2018.08.013","volume":"332","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Lin L, Li J, et al. CD4(+) T cells in obesity and obesity-associated diseases. Cell Immunol. 2018;332:1\u20136.","journal-title":"Cell Immunol"},{"key":"2242_CR43","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/1751-2980.12557","volume":"18","author":"JT Tang","year":"2017","unstructured":"Tang JT, Mao YM. Pharmacotherapy of non-alcoholic steatohepatitis: reflections on the existing evidence. J Dig Dis. 2017;18:607\u201317.","journal-title":"J Dig Dis"},{"issue":"Suppl 2","key":"2242_CR44","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12072-013-9477-5","volume":"7","author":"K Das","year":"2013","unstructured":"Das K, Chowdhury A. Lean NASH: distinctiveness and clinical implication. Hepatol Int. 2013;7(Suppl 2):806\u201313.","journal-title":"Hepatol Int"},{"issue":"Suppl 1","key":"2242_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13643","volume":"38","author":"AR Araujo","year":"2018","unstructured":"Araujo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(Suppl 1):47\u201351.","journal-title":"Liver Int"},{"key":"2242_CR46","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1053\/gast.2002.35997","volume":"123","author":"Z Li","year":"2002","unstructured":"Li Z, Lin H, Yang S, et al. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology. 2002;123:1304\u201310.","journal-title":"Gastroenterology"},{"key":"2242_CR47","doi-asserted-by":"crossref","unstructured":"Ilan Y. Immune rebalancing by oral immunotherapy: a novel method for getting the immune system back on track. J Leukoc Biol. 2018.","DOI":"10.1002\/JLB.5RU0718-276RR"},{"key":"2242_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/gut.2006.095497","volume":"56","author":"E Zigmond","year":"2007","unstructured":"Zigmond E, Preston S, Pappo O, et al. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut. 2007;56:82\u20139.","journal-title":"Gut"},{"key":"2242_CR49","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/01.tp.0000252783.66886.f3","volume":"83","author":"Y Ilan","year":"2007","unstructured":"Ilan Y, Ohana M, Pappo O, et al. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity. Transplantation. 2007;83:458\u201367.","journal-title":"Transplantation"},{"key":"2242_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11684-018-0622-3","volume":"12","author":"S Zhu","year":"2018","unstructured":"Zhu S, Zhang H, Bai L. NKT cells in liver diseases. Front Med. 2018;12:249\u201361.","journal-title":"Front Med"},{"key":"2242_CR51","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fimmu.2018.00548","volume":"9","author":"Y Nishioka","year":"2018","unstructured":"Nishioka Y, Masuda S, Tomaru U, et al. CD1d-restricted type II NKT cells reactive with endogenous hydrophobic peptides. Front Immunol. 2018;9:548.","journal-title":"Front Immunol"},{"key":"2242_CR52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2018.04.021","volume":"52","author":"RR Brutkiewicz","year":"2018","unstructured":"Brutkiewicz RR, Yunes-Medina L, Liu J. Immune evasion of the CD1d\/NKT cell axis. Curr Opin Immunol. 2018;52:87\u201392.","journal-title":"Curr Opin Immunol"},{"key":"2242_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0303-7207(97)00227-X","volume":"137","author":"PS Gill","year":"1998","unstructured":"Gill PS, Regmi A, Porter-Gill PA, et al. Interleukin-1 regulation of corticotropin-releasing factor (CRF), glucocorticoid receptor, c-fos and c-jun messenger RNA in the NPLC-KC cell line. Mol Cell Endocrinol. 1998;137:31\u20139.","journal-title":"Mol Cell Endocrinol"},{"key":"2242_CR54","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s11695-010-0181-4","volume":"20","author":"F Rabelo","year":"2010","unstructured":"Rabelo F, Oliveira CP, Faintuch J, et al. Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. Obes Surg. 2010;20:906\u201312.","journal-title":"Obes Surg"},{"key":"2242_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","volume":"166","author":"Y Tang","year":"2011","unstructured":"Tang Y, Bian Z, Zhao L, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol. 2011;166:281\u201390.","journal-title":"Clin Exp Immunol"},{"key":"2242_CR56","first-page":"296","volume":"31","author":"Y Ilan","year":"2018","unstructured":"Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol. 2018;31:296\u2013304.","journal-title":"Ann Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02242-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02242-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02242-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T07:09:18Z","timestamp":1652252958000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02242-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02242-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"After publication of the original article, it was noted that the given and family names of Ami Ben Ya\u2019acov were incorrectly structured. This has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were carried out according to the guidelines of The Hebrew University-Hadassah Institutional Committee for Care and Use of Laboratory Animals and with the committee's approval. All experimental protocols were approved by The Hebrew University-Hadassah Institutional Committee for Care. All methods were carried out in accordance with relevant guidelines and regulations. All methods are reported in accordance with ARRIVE guidelines for the reporting of animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}